MoonLake Immunotherapeutics' Promising SLK Therapy Forecasts Strong Market Performance and Stock Potential
UCB Gets FDA Approval for Bimzelx for Hidradenitis Suppurativa
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $73
MoonLake Immunotherapeutics' Promising Phase 3 Trials for PsA Treatment Drives Buy Rating
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $104
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $71